Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Canakinumab On The Progression of Type 1 Diabetes In New Onset Subjects

NCT00947427 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.

NCT NCT00947427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00947427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Canakinumab On The Progression of Type 1 Diabetes In New Onset Subjects
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
April 30, 2013
Enrollment
71 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

canakinumab in type 1 diabetes, newly diagnosed type 1 diabetes, preservation of insulin secretion, type 1 diabetes